Topotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndrome

about

Topotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndrome

Item

http://www.wikidata.org/entity/Q35937752

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

2000年论文

@zh

2000年论文

@zh-cn

name

Topotecan-based combination ch ...... anced myelodysplastic syndrome

@ast

Topotecan-based combination ch ...... anced myelodysplastic syndrome

@en

type

Item

label

Topotecan-based combination ch ...... anced myelodysplastic syndrome

@ast

Topotecan-based combination ch ...... anced myelodysplastic syndrome

@en

prefLabel

Topotecan-based combination ch ...... anced myelodysplastic syndrome

@ast

Topotecan-based combination ch ...... anced myelodysplastic syndrome

@en

P1476

Topotecan-based combination ch ...... anced myelodysplastic syndrome

@en

P2093

C C Kim

http://www.w3.org/2001/XMLSchema#string

C K Min

http://www.w3.org/2001/XMLSchema#string

D W Kim

http://www.w3.org/2001/XMLSchema#string

H J Kim

http://www.w3.org/2001/XMLSchema#string

H S Eom

http://www.w3.org/2001/XMLSchema#string

J W Lee

http://www.w3.org/2001/XMLSchema#string

S J Park

http://www.w3.org/2001/XMLSchema#string

W S Min

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia.

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.

DNA topoisomerase poisons as antitumor drugs.

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.

Multilevel therapeutic targeting by topoisomerase inhibitors.

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.

P304

122-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3904/KJIM.2000.15.2.122

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2000-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12329890

http://www.w3.org/2001/XMLSchema#string

P698

10992724

http://www.w3.org/2001/XMLSchema#string

P932

4531761

http://www.w3.org/2001/XMLSchema#string